Medical information Clinical review pending

Genetic Testing

CCM2 Gene Cerebral Cavernous Malformations Type 2 Genetic Test

Genetic test using Next-Generation Sequencing (NGS) to detect mutations in the CCM2 gene, associated with cerebral cavernous malformations (CCMs). Helps identify genetic predisposition to vascular diseases.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question

Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample: Blood sample (EDTA tube), extracted DNA, or one drop of blood on an FTA card.
Results: Approximately 3 to 4 weeks. Confirm with the laboratory before booking.
Preparation: A clinical history and genetic counseling session, including a pedigree chart of affected family members, is essential before the test. Confirm specific preparation instructions with the laboratory before booking.

Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the CCM2 Gene Cerebral Cavernous Malformations Type 2 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

Insurer or scheme name & policy / member number
A clinician's request / prescription for the test
Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

Full name *

Mobile number *

+254

Insurer or scheme

Policy / member number (optional)

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

✓Family history of cerebral cavernous malformations (CCMs).
✓Diagnosis of CCMs requiring genetic confirmation.
✓Individuals experiencing unexplained neurological symptoms like seizures or headaches.
✓Genetic counseling for individuals with a personal or family history of CCMs.
✓Family planning for individuals with a known CCM2 mutation.

In plain language

What this test helps you understand

This test helps identify individuals with mutations in the CCM2 gene, which are associated with an increased risk of developing cerebral cavernous malformations. Identifying these mutations can aid in diagnosis, prognosis, and family planning for affected individuals and their relatives.

The CCM2 Gene Cerebral Cavernous Malformations Type 2 NGS Genetic DNA Test is an advanced genetic analysis that uses Next-Generation Sequencing (NGS) technology. This test specifically looks for mutations within the CCM2 gene, which are known to be linked to the development of cerebral cavernous malformations (CCMs). CCMs are clusters of abnormal, thin-walled blood vessels found in the brain. These malformations can sometimes lead to serious health issues like bleeding in the brain (hemorrhage) or seizures. This test is particularly important for individuals who have a family history of CCMs or are experiencing symptoms potentially related to these vascular conditions. Understanding your genetic risk can help healthcare providers make informed decisions about monitoring and management. The test provides valuable insights into your genetic makeup, aiding in personalized healthcare planning.

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

Speak with us

We check the test and answer your questions before collection.

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

Understand your report

A counselor helps you understand the result and the next steps.

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →

PreparationA clinical history and genetic counseling session, including a pedigree chart of affected family members, is essential before the test. Confirm specific preparation instructions with the laboratory before booking.

SampleBlood sample (EDTA tube), extracted DNA, or one drop of blood on an FTA card.

MethodologyNext-Generation Sequencing (NGS) is used to detect mutations in the CCM2 gene.

PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.

This test only analyzes the CCM2 gene. Other genes can also be associated with cerebral cavernous malformations. A negative result does not completely rule out a genetic predisposition to CCMs. Interpretation of results requires clinical correlation and genetic counseling.

Read your report

What common result terms mean

TermPlain-language meaning

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.

NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.

VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.

Questions people ask

Frequently asked questions

CCMs are clusters of abnormal, thin-walled blood vessels in the brain that can potentially cause bleeding or seizures.

Individuals with a family history of CCMs, those diagnosed with CCMs, or people experiencing related neurological symptoms should consider this test.

The test involves analyzing a sample of your blood or DNA to look for specific mutations in the CCM2 gene.

Results indicate the presence or absence of mutations in the CCM2 gene. A genetic counselor will help explain the implications of the results.

No, this test specifically looks at the CCM2 gene. Other genes can also be involved in causing CCMs.

Your doctor or a genetic counselor will discuss the results with you, explain what they mean for your health and family, and recommend any necessary follow-up steps.

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

ACMG/AMP technical standards for sequence variant interpretation
ClinGen curation and gene–disease validity frameworks where applicable
LOINC-coded reporting for interoperable results
ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

Last updated: September 27, 2026
Medical review: not yet completed
Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Chat on WhatsApp